Mylan beats industry titans to Strides' injectables unit - The Deal Pipeline (SAMPLE CONTENT: NEED AN ID?)
Subscriber Content Preview | Request a free trialSearch  
  Go

Healthcare

Print  |  Share  |  Reprint

Mylan beats industry titans to Strides' injectables unit

by Jonathan Marino  |  Published February 28, 2013 at 8:12 AM
Several of the world's largest drugmakers have been tied to Strides Arcolab Ltd.'s injectables unit, Agila Specialties Pte. Ltd., over the past few months. But as it turns out, Mylan Inc., which hasn't made an acquisition in over two years, has claimed the prize.

Pittsburgh-based Mylan late Wednesday, Feb. 27, agreed to buy Agila for as much as $1.85 billion. Mylan will pay $1.6 billion in cash at closing and potentially up to $250 million in additional cash subject to certain unspecified conditions that Strides must satisfy.

Mylan isn't assuming any debt or acquiring any of Agila's cash through the deal. It has obtained a commitment letter from Morgan Stanley for a new $1 billion senior unsecured bridge term loan to help finance the transaction. Mylan will also use its existing credit lines and cash on hand to fund the buyout.

Both boards have approved the transaction, which is expected to close during the fourth quarter.

The deal will be immediately accretive to Mylan's adjusted diluted earnings per share when it closes.

Strides will use the proceeds to pay off debt and provide a $700 million to $800 million pre-tax return to its shareholders, the Indian company said Wednesday.

The acquisition gives Mylan one of the largest makers of injectable drugs in the world. Agila, based in Bangalore, India, produces injectable drugs including cancer therapies, antibiotics and ophthalmics. The Strides unit posted $255 million in sales and $86 million in Ebitda in 2012.

Mylan already fcosues on injectable products and believes its buyout will create a global injectables leader, while giving the company entrance into coveted high-growth international markets including Brazil. Agila has more than 300 injectables approved globally and has a presence in 70 countries.

"The addition of Agila to our existing injectables platform will immediately create a new, powerful global leader in this fast-growing market segment and accelerate our target of becoming a top-three global player in injectables," said Mylan CEO Heather Bresch in a statement.

Bresch added that Agila would further expand and diversify Mylan's portfolio of drugs, its geographic reach, and allow it to capitalize on the emerging market for biosimilars, or generic biologic drugs.

The two companies will now have more than 700 marketed injectable products and a pipeline of more than 350 others in development. Mylan CFO John Sheehan noted that Agila would nearly double its business from injectables in the first full year of integration. He added that the company still has "ample" financial flexibility to pursue other opportunities following the buyout.

Agila is rumored to have been highly sought after, with companies including Pfizer Inc., Novartis AG and others reportedly in the mix. The reason for the keen interest in Agila is the secure revenue stream that generic injectables provide while many of the world's largest producers of branded drugs deal with revenue lost from patent expirations. With more drugs such as cancer treatments going off patent, the market for generic injectables, which are difficult to produce, is increasing. Mylan noted, for example, that the market for such drugs is expected to grow at a compound annual rate of 13% through 2017.

The deal is also the third-largest acquisition of an Indian pharmaceutical entity to date, trailing only Abbott Laboratories' acquisition of Piramal Healthcare Ltd.'s healthcare solutions business ($3.72 billion) and Daiichi Sankyo Co. Ltd.'s buyout of Ranbaxy Laboratories Ltd.

The acquisition is Mylan's first buyout since July 2010, when it paid $550 million for Bioniche Pharma Holdings Ltd., also a maker of injectables.

Separately, Mylan announced its 2012 results on Wednesday, posting $1.68 billion in Ebitda on $6.8 billion in revenue.

Herbert Smith Freehills LLP is Strides' lead international counsel. Law firms DSK Legal, Haynes and Boone LLP and Pinheiro Neto Advogados also provided Strides with legal counsel.

Tommy Erdei, Dung Nguyen and Probir Rao of Jefferies & Co. were Strides' financial advisers.

A Skadden, Arps, Slate, Meagher & Flom LLP including Marie Gibson, Eric Cochran, Tim Sanders, Lorenzo Corte, Matthew Zisk, Hal Hicks, Erica Schohn, David Schwartz and Paul Doris is Mylan's legal counsel, while Slaughter and May and Platinum Partners also offered legal advice. Morgan Stanley was the buyer's financial adviser.

Share:
Tags: Agila Specialties Pte. Ltd. | Bioniche Pharma Holdings Ltd. | DSK Legal | Ebitda | Haynes and Boone LLP | Heather Bresch | Herbert Smith Freehills LLP | injectable drugs | Jefferies & Co. | John Sheehan | Morgan Stanley | Mylan Inc. | Novartis AG | Pfizer Inc. | Pinheiro Neto Advogados | Platinum Partners | Skadden Arps Slate Meagher & Flom LLP | Slaughter and May | Strides Arcolab Ltd.

Meet the journalists

Jonathan Marino

Senior Editor: Private Equity



Movers & Shakers

Launch Movers and shakers slideshow

Jones Day said former AUSA Jack M. Williams joined its Atlanta office as a partner in the business and tort litigation practice. For other updates launch today's Movers & shakers slideshow.

Video

High Road Capital's Robert Fitzsimmons shares his outlook for PE in 2015

Robert Fitzsimmons, managing partner and co-founder of private equity firm High Road Capital Partners, discusses his views on where the private equity industry is headed in 2015. Fitzsimmons also talks about attractive sectors and what's next for High Road. More video

Sectors